Immunomodulation induced by tucaresol in HIV infection: results of a 16 week pilot Phase I/II trial.
Gori
Andrea
A
Institute of Infectious Diseases and Tropical Medicine, 'L Sacco' Hospital, University of Milan, Milan, Italy. andrea.gori@unimi.it
Trabattoni
Daria
D
Bandera
Alessandra
A
Saresella
Marina
M
Marchetti
Giulia
G
Gazzola
Lidia
L
Biasin
Mara
M
Rhodes
John
J
McDade
Hugh
H
Panebianco
Ruggero
R
Galli
Massimo
M
Moroni
Mauro
M
Ferrante
Pasquale
P
Thomas
Nicola
N
Franzetti
Fabio
F
Bray
Dorothy
D
Clerici
Mario
M
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D001547:Benzaldehydes / Q000008:administration & dosage / Q000627:therapeutic use*; D001565:Benzoates / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D015497:HIV-1 / Q000235:genetics / Q000302:isolation & purification; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D020551:Pulse Therapy, Drug; D012367:RNA, Viral / Q000097:blood; D016176:T-Lymphocyte Subsets / Q000187:drug effects* / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D001547:Benzaldehydes; D001565:Benzoates; D007155:Immunologic Factors; D012367:RNA, Viral; C059629:tucaresol